Uridin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uridin

Quick Facts

Property Description
Active Ingredient Tolterodine (Tolterodine tartrate)
Form Oral dosage form (Capsule, Tablet)
Pharmacological Class Antimuscarinic Agent
General Purpose Relieves symptoms of urinary urgency and frequency
Origin Synthetic

What Type of Medicine is Uridin (Tolterodine)?

Uridin is a synthetic, prescription-only pharmaceutical preparation, containing the active substance Tolterodine (specifically, Tolterodine tartrate), which is classified as an antimuscarinic agent (Anticholinergic). This positions Uridin within the broader pharmacological category of anticholinergic agents, defining its foundational mechanism of action. The medicine is functionally identified as a urinary antispasmodic, reflecting its specific and targeted therapeutic application to the smooth muscle tissue of the lower urinary tract.

Tolterodine is a chemically synthesized small molecule that works by acting as a competitive antagonist against acetylcholine, the nerve messenger that triggers muscle contraction. This mechanism is clinically recognized for its ability to modulate nerve signals sent to the bladder muscle. While the comprehensive class of anticholinergic compounds affects various systems, Tolterodine is noted for its high functional selectivity for muscarinic receptors located predominantly within the bladder wall.

Composition and Available Forms of Uridin

Uridin is manufactured as a single-ingredient product, with Tolterodine being the sole therapeutic compound, and is supplied as an oral dosage form. It is primarily available to patients as a capsule or a tablet, intended to be taken by mouth.

The pharmaceutical preparation is frequently designed in two main formats: an immediate-release (IR) form and an extended-release (LA or ER) form. The difference lies in the release profile of the active substance: the IR form delivers Tolterodine into the system quickly, while the ER capsule ensures the drug, which metabolizes to the active 5-hydroxymethyl metabolite, is released slowly and consistently over an extended duration.

The General Purpose of Uridin's Mechanism

The general purpose of Uridin is to help individuals address symptoms caused by the involuntary activity of the bladder muscle by acting as a muscle stabilizer. By interfering with the nerve signals that cause contraction, the medication helps to relax the detrusor muscle within the bladder wall.

This resulting physiological action reduces the abnormal, spontaneous, and uncontrolled bladder contractions that lead to functional problems. The outcome is an increase in the bladder’s capacity, which directly supports the primary benefit: to relieve the disruptive symptoms of persistent urinary urgency and bothersome urinary frequency.

What side effects are possible with Uridin?

Possible Side Effects and Safety Information

As an antimuscarinic agent, the safety profile of Uridin (Tolterodine) is defined by its class-related effects, which are officially categorized by frequency observed in clinical data.

The most frequently reported adverse reaction is Dry Mouth (Xerostomia), classified as Very Common in regulatory documents. Other adverse effects classified as Common include Headache, Dizziness, Constipation, Abdominal Pain, Dyspepsia, Fatigue, and Dry Eyes.

System-Organ Classification

Side effects are grouped by the affected body system. Common reports affect the Gastrointestinal Disorders (e.g., Constipation) and Nervous System Disorders (e.g., Somnolence, Dizziness). Uncommon effects include Urinary Retention, Palpitations, and Arrhythmia, with Convulsions classified as Rare.

Serious Safety Considerations and Restrictions

Official labels document the possibility of Serious Adverse Reactions, including severe hypersensitivity events such as Anaphylaxis and Angioedema, which may require emergency medical treatment. Due to its potential impact on cardiac electrical activity, a risk of QT prolongation is noted, especially in susceptible individuals.

Use of Uridin is officially Contraindicated in individuals with pre-existing conditions that are known to be worsened by antimuscarinic action, such as Urinary Retention, Gastric Retention, and Uncontrolled Narrow-Angle Glaucoma.

Population-Specific Safety Notes are defined for patients with organ impairment: use is not recommended in those with Severe Hepatic Impairment, and a dose adjustment is officially required for patients with Severe Renal Impairment.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Uridin

The regulatory information for Uridin (Uridine Triacetate) focuses on the medicine's safety profile rather than a defined syndrome of acute overdose. The official prescribing documentation does not formally describe a severe or life-threatening systemic syndrome resulting directly from an overdose of Uridin itself.

Documented Manifestations of Overexposure

The clinical manifestations most frequently documented in association with the medicine are focused on the gastrointestinal system, as derived from the medicine’s adverse reaction profile at therapeutic doses. These manifestations include:

  • Nausea
  • Vomiting
  • Diarrhea

No unique, severe physiological or cardiovascular complications are described in the official labeling as being attributable to an overdose of Uridin.

Mandated Emergency Actions and Antidote

  • Antidote: No specific antidote for Uridine Triacetate overdose is described in the official regulatory information.
  • Emergency Response: The official documentation does not contain explicit, regulator-mandated protocols for emergency actions, specific monitoring, or supportive measures directed at a Uridin overdose.

When to Seek Urgent Medical Help

As a severe overdose syndrome is not detailed in the official regulatory documents, no specific clinical threshold or symptom is defined in the label for when urgent medical help must be sought for overexposure to Uridin itself.

Therapeutic Uses of Uridin

Quick Facts

  • Emergency Care: May be administered in the context of certain chemotherapy overdose or severe toxicity.
  • Metabolic Support: Used to manage the rare inherited condition, hereditary orotic aciduria.

Uridin (as the approved form, uridine triacetate) is a prescription medication utilized for specific, regulated therapeutic purposes. The medication's primary applications fall into two main areas of care.

It is indicated as a key component of emergency treatment for adults and pediatric patients who have received an overdose of the cancer medicines fluorouracil or capecitabine. This intervention is also employed for individuals who develop early-onset, serious, or life-threatening toxicities, such as those impacting the cardiac or central nervous system, following the administration of these specific chemotherapy agents. The goal of this use is to offer support against cellular damage and adverse effects resulting from the overdose or severe toxicity.

Additionally, Uridin is medically utilized as a form of replacement therapy in the management of hereditary orotic aciduria, a rare inherited metabolic disorder. In this context, it functions to address the underlying deficiency associated with the condition.

Eligibility and Restrictions for Use

Uridin (uridine triacetate) is used for specific medical conditions, primarily as an emergency rescue treatment for patients following an overdose of the chemotherapy medications fluorouracil or capecitabine. It is also prescribed for the long-term management of a rare genetic disorder called hereditary orotic aciduria.

Who Can and Cannot Use Uridin

Group/Condition Status Clinical Rationale/Precaution
Hereditary Orotic Aciduria Can Use Indicated for treatment to provide a source of uridine.
Fluorouracil/Capecitabine Toxicity Can Use Indicated as an emergency antidote/rescue treatment.
Allergy to Uridin Cannot Use Contraindicated in individuals with a known hypersensitivity to the drug or its components.
Pregnancy/Breastfeeding Precaution Limited human data. Risk versus benefit must be carefully assessed by a physician.
Non-Emergent Toxicity Precaution Not recommended for non-emergent use as it may reduce the efficacy of the chemotherapy drugs.

Consultation with a healthcare professional is mandatory before starting Uridin, particularly in cases of pre-existing conditions or when taking other medications, to ensure its safe and appropriate use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Uridin (Tolterodine) is defined by pharmacokinetic changes and pharmacodynamic additive effects, as documented in official regulatory information.

Interaction Type Interacting Substances / Conditions Formal Outcome Statement
Metabolic (Pharmacokinetic) Potent CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin), Potent CYP2D6 Inhibitors (e.g., fluoxetine) Co-administration via metabolic inhibition results in a documented increase in systemic exposure (AUC/Cmax) of the parent drug.
Additive (Pharmacodynamic) Other Anticholinergic Agents, QTc-Prolonging Agents (e.g., Class IA and III antiarrhythmics) Increased potential for additive antimuscarinic effects. Co-administration with QTc-prolonging agents requires consideration due to potential additive QTc prolongation.
Drug-Food Food intake Documented increase in the bioavailability of the drug by an average of 53%.
Population-Specific Severe Renal Impairment, Hepatic Insufficiency Systemic exposure to the active moiety is 2- to 3-fold higher in these populations, which increases the clinical significance of potential drug interactions.

Connection to the overall interaction profile

The regulatory profile is characterized by clinically significant pharmacokinetic interactions tied to the inhibition of CYP enzyme pathways, which formally raises the drug’s plasma levels. Though no mandatory timing separation rules are documented, pharmacodynamic interactions impose a required consideration for additive antimuscarinic effects and a QTc-prolonging risk when combined with specific medicinal product classes. These interaction risks are formally stated to be more pronounced in patients with documented hepatic or renal insufficiency due to altered clearance.

Mechanism of Action

Blocking the Detrusor Contraction Signal

The pharmacodynamic mechanism of Uridin involves the combined action of Tolterodine and its active 5-hydroxymethyl metabolite as a competitive muscarinic antagonist. This active moiety physically blocks the mathbfM3 subtype of muscarinic receptors on the detrusor smooth muscle cells, preventing the neurotransmitter Acetylcholine (ACh) from binding and initiating the signal necessary for smooth muscle depolarization.

Modulating Muscle Tone and Bladder Capacity

By interrupting this cholinergic signaling pathway, the mechanism promotes the relaxation of the detrusor muscle, reducing its excitability and basal tone. This causes a physiological consequence: a reduction in detrusor pressure during the filling phase and a resulting increase in bladder volume accommodation. The action exhibits functional tissue selectivity in the urinary tract, notwithstanding the drug's mathbfM1-mathbfM5 non-selective antagonism.

Affecting Bladder Sensory Feedback

Beyond the muscle itself, the mechanism also influences muscarinic receptors on urothelial and suburothelial cells. This action modulates the afferent nerve signaling, affecting the transmission of sensory input from the bladder to the central nervous system. This dual-pathway modulation contributes to the overall pharmacodynamic activity in the lower urinary tract.

Dosage and Administration Information

Uridin (Uridine Triacetate) is administered according to two distinct, regulated protocols based on the clinical scenario, following the official administration guidelines. The approved route of administration is oral ingestion, although administration via nasogastric (NG) tube or gastrostomy (G-Tube) is permitted in specific patient circumstances.

Administration Protocols

Indication Standard Adult Dosing Frequency and Duration
Emergency Treatment 10 grams (one packet) per dose. Administered every 6 hours (q6h) for a total course of 20 doses. Treatment initiation must occur within 96 hours following the end of chemotherapy administration.
Hereditary Orotic Aciduria Initial dose is 60 milligrams per kilogram (mg/kg) of body weight once daily. The dose may not exceed 120 mg/kg daily. Administered once daily as a long-term replacement therapy.

Preparation and Specific Use Conditions

The medicine may be taken without regard to meals. Preparation requires mixing the granules with 3 to 4 ounces of soft food, such as applesauce or yogurt. This mixture must be consumed within 30 minutes of preparation, and the granules must not be chewed. Following ingestion of the dose, the patient must consume a minimum of 4 ounces of water.

For pediatric use in the emergency setting, the dose is calculated based on body surface area (BSA) at 6.2 grams per square meter (6.2 g/m^2) per dose, not to exceed 10 grams. If a dose is vomited within 2 hours during emergency treatment, a complete replacement dose must be administered as soon as possible, with the next dose following the original schedule. The specialized dosing and frequency rules ensure the medicine is delivered according to established standards for its specific uses.

Recent Clinical Evidence

Uridine: Recent Clinical Evidence

Uridine, a naturally occurring pyrimidine nucleoside, plays a fundamental role in the synthesis of RNA and cell membrane components. Clinical research has primarily focused on its use in combination with other agents, particularly B vitamins and cytidine, for nerve-related conditions.


Focus on Neuropathy and Nerve Pain

Studies have investigated the impact of uridine monophosphate (UMP) combined with B vitamins (such as B12 and folic acid) in individuals experiencing chronic pain associated with nerve compression or damage, including diabetic peripheral neuropathy. Research in animal models suggests that uridine may contribute to the metabolic activity necessary for the repair of damaged myelin sheaths and nerve fibers, which are essential structures for nerve conduction.

One randomized study comparing a combination of nucleotides (UMP/CMP) and Vitamin B12 to Vitamin B12 alone in patients with neuralgia demonstrated a more pronounced improvement in pain reduction measures for the combination group. Subsequent observational and clinical evaluations have further explored these combinations in conditions like lumbar pain, cervical pain, and radiculopathy, tracking outcomes such as pain intensity and functional measures.


Other Approved Uses

Uridine triacetate, a prodrug of uridine, is approved for specific therapeutic applications that utilize uridine's metabolic pathways. These include the emergency management of severe toxicity or overdose caused by the chemotherapy agents fluorouracil and capecitabine, where uridine competes with the toxic metabolites. It is also utilized in the treatment of the rare genetic disorder, hereditary orotic aciduria, by supplementing the body's pyrimidine nucleotide pool.

Key Studies & References

  1. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies

Frequently Asked Questions (FAQ)

Common questions about Uridin (FAQ)

Q: Does Uridin interact with birth control pills?

A: Official studies examined the co-administration of Uridin and a combined oral contraceptive. Regulatory documents state that no clinically relevant interactions were observed when Uridin was co-administered with a combined pill containing ethinyl estradiol and levonorgestrel.


Q: What does the research say about Uridin and long-term liver health?

A: Regulatory information addresses Uridin’s use in individuals who already have impaired liver function. Official regulatory documents note that a dosage adjustment is required for individuals with mild to moderate hepatic impairment. Use is not recommended for those with severe hepatic impairment.


Q: Can Uridin affect a person's ability to drive or operate machinery?

A: Uridin may affect the central nervous system. Official labeling indicates that operating heavy machinery or driving should be avoided until an individual knows how the medicine affects them, due to the potential for effects such as dizziness and somnolence (drowsiness).


Q: What is the consensus on Uridin's use during pregnancy, according to official sources?

A: According to official sources, there is limited human data available on the use of Uridin during pregnancy. Official product information indicates that the potential risk versus benefit is subject to careful assessment by a healthcare professional prior to use.


Q: How long after stopping Uridin can I start taking a new, interacting medicine?

A: Regulatory documents do not specify a mandatory time separation or 'washout period' after stopping Uridin before beginning an interacting medicine. Decisions about timing are based on a healthcare provider’s evaluation of the full interaction profile.


Q: Why do official documents list so many different side effects if only a few are common?

A: Official documents categorize side effects by the frequency they were observed in clinical data, ranging from Very Common to Rare. This comprehensive listing is required by regulatory agencies to provide full transparency regarding the drug’s overall safety profile.


Q: Is Uridin the same as the supplement I see advertised online?

A: No. Uridin is officially classified by regulatory agencies as a synthetic, prescription-only pharmaceutical product. It is regulated for use as a prescription medicine and is not available as an over-the-counter or dietary supplement.


Q: Why is Uridin sometimes referred to by a different name?

A: The medicine may be referred to by different names because the active ingredient, Tolterodine, is manufactured and sold under various brand names as approved by regulatory agencies. Brand names often vary by country and manufacturer.


Q: How quickly can a person expect Uridin to start working?

A: Clinical pharmacology data provides information on how soon the drug begins to act on the body. Effects on physical parameters, such as a decrease in detrusor pressure, have been measured as early as 1 to 5 hours following administration of an immediate-release dose.


Q: How long does Uridin usually stay in your system?

A: The length of time the drug remains in the system is related to its half-life. Official prescribing information states that the elimination half-life of Uridin (tolterodine) is approximately 2.4 hours, and the half-life of its active metabolite is approximately 3.0 to 3.3 hours.


Q: What happens if I forget to use Uridin for one day?

A: Official patient instructions indicate that if a dose is missed, the medicine is to be resumed at the next regularly scheduled time. It is specifically advised not to take two doses in the same day.


Q: Do I need to avoid any specific foods or drinks while using Uridin?

A: The medicine may be taken without regard to meals. However, regulatory information notes that beverages containing caffeine may aggravate the symptoms Uridin is used to treat. Additionally, significant alterations in grapefruit juice intake are noted to potentially affect drug metabolism.


Q: Is it normal to feel a mild stomach discomfort when starting Uridin?

A: Regulatory documents address this by classifying Abdominal Pain as a Common adverse reaction associated with the use of this medicine.


Q: Is Uridin considered a steroid?

A: No, Uridin is not a steroid. It is officially classified as a synthetic antimuscarinic agent (anticholinergic). This classification defines its specific action on nerve signals and muscle receptors.


Q: Can Uridin be used by older adults?

A: Official safety data has examined Uridin's use in the elderly. In clinical studies, no overall differences were observed in safety between older and younger patients, meaning no general dose adjustment is recommended solely based on age.


Q: Is Uridin safe to use for people with kidney problems?

A: Official regulatory information provides specific guidance for use based on the level of kidney function. A dose adjustment is required for individuals with severe renal impairment. Use is not recommended for those with creatinine clearance below 10 mL/min.


Q: Are there any documented interactions between Uridin and herbal supplements?

A: Regulatory information provides a general caution regarding potential interactions. The drug’s effects can be influenced by other products, including prescription and non-prescription medicines, vitamins, and herbal products.


Q: Can Uridin be used by people with a history of heart issues?

A: The medicine's label notes a risk of QT prolongation, which is a change in the electrical activity of the heart. Official documentation notes that patients with a personal or family history of long QT syndrome are to discuss this with their healthcare provider.


Q: What did the main clinical studies on Uridin conclude about its effects?

A: Clinical studies found that the drug's effects are consistent with an antimuscarinic action on the lower urinary tract. This action results in physiological changes, including a decrease in detrusor pressure during the filling phase and an increase in residual urine.


Q: What should be done if I experience a very rare side effect listed for Uridin?

A: Official patient information indicates that, in the event of symptoms suggesting a serious adverse reaction, the medicine is to be discontinued and immediate medical attention is to be sought. This includes severe hypersensitivity events, such as swelling or difficulty breathing.


Q: Are there any known interactions between Uridin and caffeine?

A: Regulatory information notes that beverages containing caffeine may potentially decrease the action of Uridin. This is because caffeine is a diuretic, which may counteract the drug’s primary purpose of managing urinary frequency.


Q: Can Uridin cause problems with vision?

A: Yes, Uridin can cause vision-related issues due to its anticholinergic properties. Adverse effects reported in regulatory documents include blurred vision and dry eyes.


Q: Why is Uridin not recommended for people with certain specific allergies?

A: The medicine is officially contraindicated for individuals with a known hypersensitivity (allergy) to the drug or any of its specific ingredients. This is a standard safety measure to prevent severe allergic reactions.


Q: Does alcohol consumption interfere with how Uridin works?

A: Regulatory information indicates that the consumption of alcohol may potentially increase central nervous system effects of the medicine. These effects can include increased drowsiness and dizziness.


Q: Is the effectiveness of Uridin influenced by a person's age?

A: Clinical data from studies suggest that advanced age may be associated with a slight but statistically significant decrease in treatment efficacy. However, as noted in official safety data, no overall differences in safety were found for the geriatric population.


Q: What percentage of users in clinical trials reported common side effects with Uridin?

A: Specific frequency data is provided in the clinical trials section of regulatory documents. For example, in a 12-week study, Dry Mouth was reported by 23.4% of patients, and Constipation was reported by 7% of patients.

How should Uridin be stored and disposed of?

How to Store and Dispose of Uridin

Uridin (uridine triacetate) must be stored and handled according to the official specifications provided in its regulatory labeling to maintain product stability.

Official Storage Requirements

Item Requirement
Temperature Store at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F).
Container Keep in the original bottle and ensure the bottle is tightly closed.
Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Uridin must be disposed of properly. Do not dispose of the medication in household trash or by flushing it down a toilet. The official procedure is to utilize a drug take-back program or follow the specific instructions provided by a pharmacist or local waste disposal service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uridin found in:

A-Z Index: